HFA Icon

Gilead Sciences: Hepatitis C and Hedge Fund Profiteers – Hedge Clippers

HFA Padded
Guest Post
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

This is the latest from Hedge Clippers – we thought readers would enjoy the read for the info (and the humor).

Gilead Sciences: Hepatitis C and Hedge Fund Profiteers by Hedge Clippers

Meet The Hedge Fund Managers Cashing In On Predatory Drug Pricing Schemes from Gilead Sciences

For millions of Americans infected with Hepatitis C, the inflated prices of new Hepatitis C drugs from Gilead Sciences translate into limited access and prolonged illness.

The pharmaceutical giant is charging as much as $1,125 per pill and $94,500 for a course of its lifesaving treatments, forcing health care systems to limit access, robbing patients of a decent quality of life, and forcing many into serious health problems and complications.

Hedge...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

If you are interested in contributing to Hedge Fund Alpha on a regular or one time basis read this post